S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Mutations in genes in the retinal pigment epithelium (RPE) cause or contribute to debilitating ocular diseases, including Leber's congenital amaurosis (LCA). Genetic therapies, particularly adeno-associated viruses (AAVs), are a popular choice for monogenic diseases; however, the limited payload capacity of AAVs combined with the large number of retinal disease genes exceeding that capacity make the development of alternative delivery methods critical. Here, we test the ability of compacted DNA nanoparticles (NPs) containing a plasmid with a scaffold matrix attachment region (S/MAR) and vitelliform macular dystrophy 2 (VMD2) promoter to target the RPE, drive long-term, tissue-specific gene expression and mediate proof-of-principle rescue in the rpe65(-/-) model of LCA. We show that the S/MAR-containing plasmid exhibited reporter gene expression levels several fold higher than plasmid or NPs without S/MARs. Importantly, this expression was highly persistent, lasting up to 2 years (last timepoint studied). We therefore selected this plasmid for testing in the rpe65(-/-) mouse model and observe that NP or plasmid VMD2-hRPE65-S/MAR led to structural and functional improvements in the LCA disease phenotype. These results indicate that the non-viral delivery of hRPE65 vectors can result in persistent, therapeutically efficacious gene expression in the RPE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Outstanding studies from Naash and colleagues showed that rod-shaped CK30-PEG (polyethylene glycol)-compacted NPs effectively transfected both RPE and photoreceptors and showed efficacious gene therapy of Rpe65−/− (retinal pigment epithelium 65; model of LCA) and Abca4−/− (Stargardt Disease) mice [39,40,41].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [41]
Experimental — accuracy not yet measuredIn the citing paper
“These plasmid modifications have been shown to be effective in gene delivery in Rpe65−/−, Abca4−/− and Rhodopsin−/− [41,45,46].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 1×
“Although adeno-associated virus (AAV)-based vectors have been successful for ocular gene therapy (3–5), they are limited by their payload capacity which is ,5 kb (6).”
BackgroundRpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929 · cited 4×
“Functionally, rpe65 mice exhibit minimal or no scotopic retinal function, reduced MWL green-cone signal and extinguished SWL UV-cone signals (34,38).”
BackgroundInfluentialCideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Diseases Caused by Defects in the Visual Cycle: Retinoids as Potential Therapeutic Agents
Travis, G. H., Golczak, M., Moise, A. R., & Palczewski, K. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105225 · Cited by 419
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256 · cited 1×
“Mice were treated at postnatal day 16, since early treatment has provided better improvements in LCA phenotypes (32,33).”
MethodPang, J., Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Li, J., Noorwez, S. M., Malhotra, R., McDowell, J. H., Kaushal, S., et al. (2005) · PubMed · Cited by 227
Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208 · cited 1×
“We have shown that these NPs efficiently transfect both photoreceptors (8–10) and RPE cells (9,11) and can improve the disease phenotype in the rds+/2 model of retinitis pigmentosa (8,10).”
BackgroundSelf-citationChromatin loops are selectively anchored using scaffold/matrix-attachment regions
Heng, H. H. Q., Goetze, S., Ye, C. J., Liu, G., Stevens, J. B., Bremer, S. W., Wykes, S. M., Bode, J., & Krawetz, S. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00976 · Cited by 204
Research works printed but not linked: 1
- Han Z., Koirala A., Makkia R., Cooper M.J., Naash M.I. Direct gene transfer with compacted DNA nanoparticles in retinal pigment epithelial cells: expression, repeat delivery and lack of toxicity . Nanomedicine (Lond) 2012;7:521–539. doi: 10.2217/nnm.11.158. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Barriers to inhaled gene therapy of obstructive lung diseases: A review
Kim, N., Duncan, G. A., Hanes, J., & Suk, J. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.031 · Cited by 118
Rajala, A., Wang, Y., Zhu, Y., Ranjo-Bishop, M., Ma, J.-X., Mao, C., & Rajala, R. V. S. (2014) · Nano Letters · doi:10.1021/nl502275s · Cited by 117
Nanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Self-citationLipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
BackgroundMethodTreatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases
Kansara, V., Muya, L., Wan, C.-R., & Ciulla, T. A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0126 · Cited by 84
“Han et al. successfully transfected RPE cells at a higher efficiency than naked DNA after subretinal administration without significant toxicity.46 Koirala et al. tested the ability of compacted DNPs to target the RPE, driving long-term, tissue-specific gene expression, and mediating proof-of-principle rescue in the r…”
BackgroundGene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74
Self-citationA review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium
Koirala, A., Conley, S. M., & Naash, M. I. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.002 · Cited by 71
Self-citationVectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gall, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 66
Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments
Mitsios, A., Dubis, A. M., & Moosajee, M. (2018) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841418817490 · Cited by 61
Synthesis and Characterization of Glycol Chitosan DNA Nanoparticles for Retinal Gene Delivery
Mitra, R. N., Han, Z., Merwin, M., Al Taai, M., Conley, S. M., & Naash, M. I. (2014) · ChemMedChem · doi:10.1002/cmdc.201300371 · Cited by 56
Self-citationGenomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype
Han, Z., Banworth, M. J., Makkia, R., Conley, S. M., Al‐Ubaidi, M. R., Cooper, M. J., & Naash, M. I. (2015) · The FASEB Journal · doi:10.1096/fj.15-270363 · Cited by 54
“Although we have shown that vectors delivered via CK30-PEG NPs continue generating excellent expression in the RPE for several years (12, 25), we have routinely observed decreased NP-mediated gene expression in photoreceptors over time (21, 22).”
BackgroundMethodSelf-citationDirecting the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 53
Insights into the mechanisms of macular degeneration associated with the R172W mutation in RDS
Conley, S. M., Stuck, M. W., Burnett, J. L., Chakraborty, D., Azadi, S., Fliesler, S. J., & Naash, M. I. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu014 · Cited by 51
Self-citationGene Therapy for PRPH2-Associated Ocular Disease: Challenges and Prospects
Conley, S. M., & Naash, M. I. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017376 · Cited by 51
Self-citationNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Self-citationNanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy
Mitra, R. N., Nichols, C. A., Guo, J., Makkia, R. S., Cooper, M. J., Naash, M. I., & Han, Z. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.020 · Cited by 49
Self-citationSun, D., Sahu, B., Gao, S., Schur, R. M., Vaidya, A. M., Maeda, A., Palczewski, K., & Lu, Z.-R. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.02.005 · Cited by 47
“In future work, we will address the transience of gene expression with these nanoparticles by modifying the DNA plasmid with sequences that prolong gene expression, such as scaffold/matrix attachment regions (S/MARs).(41) The targeted ECO/pDNA nanoparticles can also be further optimized by introducing a pH-sensitive s…”
BackgroundKoirala, A., Conley, S. M., Makkia, R., Liu, Z., Cooper, M. J., Sparrow, J. R., & Naash, M. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.299 · Cited by 47
Self-citationMagnetic nanoparticles: a strategy to target the choroidal layer in the posterior segment of the eye
Giannaccini, M., Pedicini, L., Matienzo, G. D., Chiellini, E., Dente, L., & Raffa, V. (2017) · Scientific Reports · doi:10.1038/srep43092 · Cited by 47
The Y141C knockin mutation in RDS leads to complex phenotypes in the mouse
Stuck, M. W., Conley, S. M., & Naash, M. I. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu345 · Cited by 45
Self-citationAdvances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy
Mulia, G. E., Picanço‐Castro, V., Stavrou, E. F., Athanassiadou, A., & Figueiredo, M. L. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.310 · Cited by 42
DNA-Based Nonviral Gene Therapy─Challenging but Promising
Guan, X., Pei, Y., & Song, J. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00907 · Cited by 39
DNA nanoparticles are safe and nontoxic in non-human primate eyes
Kelley, R. A., Conley, S. M., Makkia, R., Watson, J. N., Han, Z., Cooper, M. J., & Naash, M. I. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s157000 · Cited by 36
Self-citationLee, H., & Noh, H. (2023) · Gels · doi:10.3390/gels9090718 · Cited by 36
Effective gene therapy of Stargardt disease with PEG-ECO/pGRK1-ABCA4-S/MAR nanoparticles
Sun, D., Sun, W., Gao, S., Lehrer, J., Naderi, A., Wei, C., Lee, S.-J., Schilb, A. L., Scheidt, J. H., Hall, R. C. W., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.026 · Cited by 35
The utility and risks of therapeutic nanotechnology in the retina
Scheive, M., Yazdani, S., & Hajrasouliha, A. R. (2021) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414211003381 · Cited by 35
Novel molecular mechanisms for Prph2‐associated pattern dystrophy
Chakraborty, D., Strayve, D., Makia, M. S., Conley, S. M., Kakakhel, M., Al‐Ubaidi, M. R., & Naash, M. I. (2019) · The FASEB Journal · doi:10.1096/fj.201901888r · Cited by 33
Self-citationMitra, R. N., Zheng, M., Weiss, E. R., & Han, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.12.004 · Cited by 32
Improvement in vision: a new goal for treatment of hereditary retinal degenerations
Jacobson, S. G., Cideciyan, A. V., Aguirre, G. D., Román, A. J., Sumaroka, A., Hauswirth, W. W., & Palczewski, K. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1030393 · Cited by 32
Bohley, M., Dillinger, A. E., Tamm, E. R., & Göpferich, A. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.024 · Cited by 29
The K153Del PRPH2 mutation differentially impacts photoreceptor structure and function
Chakraborty, D., Conley, S. M., Zulliger, R., & Naash, M. I. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw193 · Cited by 29
Self-citationThe Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28
“These plasmid modifications have been shown to be effective in gene delivery in Rpe65−/−, Abca4−/− and Rhodopsin−/− [41,45,46].”
Miller, L. R., Tarantini, S., Nyúl-Tóth, Á., Johnston, M. P., Martin, T., Bullen, E. C., Bickel, M. A., Sonntag, W. E., Yabluchanskiy, A., Csiszar, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.788296 · Cited by 28
Self-citationThe Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases
Toualbi, L., Toms, M., & Moosajee, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052318 · Cited by 23
Successful large gene augmentation of USH2A with non-viral episomal vectors
Toms, M., Toualbi, L., Almeida, P. V., Harbottle, R. P., & Moosajee, M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.012 · Cited by 23
Nanoparticle‐motivated gene delivery for ophthalmic application
Mitra, R. N., Zheng, M., & Han, Z. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1356 · Cited by 21
Synthetic nanocarriers for the delivery of polynucleotides to the eye
Saraiva, S. M., Castro-López, V., Pañeda, C., & Alonso, M. J. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.001 · Cited by 21
Gil, C.-H., Chakraborty, D., Vieira, C. P., Prasain, N., Calzi, S. L., Fortmann, S. D., Hu, P., Banno, K., Jamal, M., Huang, C., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm5559 · Cited by 21
Episomal Maintenance of S/MAR-Containing Non-Viral Vectors for RPE-Based Diseases
Koirala, A., Conley, S. M., & Naash, M. I. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_88 · Cited by 20
Self-citationAdvancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Panikker, P., Roy, S., Ghosh, A., Poornachandra, B., & Ghosh, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906482 · Cited by 19
Graceffa, V. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00194-3 · Cited by 19
Chan, S., Bubela, T. M., Dimopoulos, I. S., Freund, P. R., Varkouhi, A. K., & MacDonald, I. M. (2016) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1088958 · Cited by 17
Rocco, D., Pompili, B., Castellani, S., Morini, E., Cavinato, L., Cimino, G. G., Mariggiò, M. A., Guarnieri, S., Conese, M., Porto, P. D., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041220 · Cited by 15
Minicircle Delivery to the Neural Retina as a Gene Therapy Approach
Staurenghi, F., McClements, M. E., Salman, A., & MacLaren, R. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911673 · Cited by 15
Nanotherapy for Neural Retinal Regeneration
Yu, C., Dong, L., Lv, Y., Shi, X., Zhang, R., Zhou, W., Wu, H., Li, H., Li, Y., Zhou, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202409854 · Cited by 13
Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders
Jony, M. J. H., Joshi, A., Dash, A. K., & Shukla, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010087 · Cited by 12
Major, L., McClements, M. E., & MacLaren, R. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087603 · Cited by 12
Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases
Wang, Y., Rajala, A., & Rajala, R. V. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_15 · Cited by 12
Effective intravitreal gene delivery to retinal pigment epithelium with hyaluronic acid nanospheres
Crane, R., Makia, M. S., Zeibak, S., Tebbe, L., Ikelle, L., Woods, C. R., Conley, S. M., Acharya, G. S., Naash, M. I., & Al‐Ubaidi, M. R. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102222 · Cited by 9
Self-citationA Novel Nonviral Gene Delivery System for Treating Leber's Congenital Amaurosis
Sun, D., Schur, R. M., & Lu, Z. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0072 · Cited by 9
Eblimit, A., Makia, M. S., Strayve, D., Crane, R., Conley, S. M., Sinha, T., Acharya, G. S., Al‐Ubaidi, M. R., & Naash, M. I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091510 · Cited by 8
Self-citationBinder, C., Cashman, S. M., & Kumar‐Singh, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082295 · Cited by 8
Zulliger, R., Watson, J. N., Al‐Ubaidi, M. R., Padegimas, L., Sesenoglu‐Laird, O., Cooper, M. J., & Naash, M. I. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_14 · Cited by 8
Self-citationNon-viral gene therapy for Leber’s congenital amaurosis: progress and possibilities
Abdulsalam, L., Mordecai, J., & Ahmad, I. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2443387 · Cited by 7
Delivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies
Gemayel, M. C., Byrne, L. C., Ciulla, T. A., & Sahel, J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000360 · Cited by 5
Gene Augmentation of CHM Using Non-Viral Episomal Vectors in Models of Choroideremia
Toualbi, L., Toms, M., Almeida, P. V., Harbottle, R. P., & Moosajee, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015225 · Cited by 5
DNA- and RNA-based Gene Therapies in Ophthalmology
Ciulla, T. A., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000359 · Cited by 4
Gene Therapy Using Genomic DNA
Han, Z. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00003-x · Cited by 4
Exploration: Nanoparticles in the Diagnosis and Treatment of Retinal Diseases
Wang, L., Xie, W., Chen, J., Zhao, L., Wen, Y., Xie, H., Shu, Q., Pan, F., Lu, J., Liu, Y., et al. (2023) · Journal of Nanomaterials · doi:10.1155/2023/9099778 · Cited by 4
A Simple Nonviral Method to Generate Human Induced Pluripotent Stem Cells Using SMAR DNA Vectors
Hartley, A., Burger, L., Wincek, C. L., Dons, L., Li, T. M. W. Y., Grewenig, A., Taşgın, T., Urban, M. B., Roig‐Merino, A., Ghazvini, M., et al. (2024) · Genes · doi:10.3390/genes15050575 · Cited by 3
Wang, F., Zhang, J. H., Wang, T.-Z., Dong, W. H., Yang, X., Wang, X. Y., Wang, L., Yang, R., Li, Q., & Zhao, C. (2015) · Genetics and Molecular Research · doi:10.4238/2015.june.26.12 · Cited by 3
Stieger, K., & Lorenz, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-28384-1_15 · Cited by 2
Nonviral Delivery Systems for Gene Therapy for Retina and Posterior Segment Disease
del Pozo‐Rodríguez, A., Torrecilla, J., Rodríguez‐Gascón, A., & Solinís, M. Á. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_8 · Cited by 2
Ameline, B. (2016) · theses.fr (ABES) · doi:10.70675/7e510195z896bz4be6za7d5z616677c5bfa2 · Cited by 2
Administration of Ocular Gene Therapy
Xu, D. N., Khan, M., Klufas, M. A., & Ho, A. C. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000365 · Cited by 1
Evolution dirigée de virus adéno-associés pour un transfert de gène efficace dans le système visuel
Planul, A. (2017) · theses.fr (ABES) · doi:10.70675/c9b178a1z8ba4z4451za409z4e80a603376f · Cited by 1
In Vivo Selection of S/MAR Sequences to Favour AAV Episomal Maintenance in Dividing Cells
Llanos-Ardaiz, A., Lantero, A., Neri, L., Mauleón, I., de Galarreta, M. R., Trigueros‐Motos, L., Weber, N. D., Ferrer, V., Aldabe, R., & González‐Aseguinolaza, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312734 · Cited by 1
Potential and pitfalls of non-viral mRNA delivery for ocular therapies
Devoldere, J. (2019) · Ghent University Academic Bibliography (Ghent University) · Cited by 1
Gene Therapy for Neurological Disorders: Molecular Approaches for Targeted Treatment
Malviya, R., Singh, A. K., Goyal, P., & Sundram, S. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003494102 · Cited by 1
Yang, R., Li, Z., Lin, Y., Yang, B., & Wang, T. (2013) · BioMed Research International · doi:10.1155/2013/862450 · Cited by 1
Amberger, M. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.81592
Stieger, K., & Lorenz, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-35055-9_15
Karamichos, D. (2016) · MDPI eBooks · doi:10.3390/books978-3-03842-202-0
Rethinking nonsense suppression therapies in inherited retinal diseases
Ren, C., Hu, C., Hu, M., Yang, Y., & Lu, F. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.09.017
Pattern Dystrophies of the RPE
Allan, K. C., & Yuan, A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0042
Toualbi, L. (2024) · UCL Discovery (University College London)
DEVELOPMENT OF GENE THERAPIES FOR INHERITED RETINAL DEGENERATIONS: A NON-VIRAL APPROACH
Sun, D. (2018) · OhioLink ETD Center (Ohio Library and Information Network)
Torras, A. S., & Universitat Autònoma de Barcelona. Departament d'Enginyeria Química, B. I. A. (2017) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Relatórios de Estágio e Monografia intitulada “Polymeric Nanoparticles for Ocular Gene Therapy”
Sequeira, C. V. S. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Metadata
- Authors
- Koirala, A., Makkia, R. S., Conley, S. M., Cooper, M. J., & Naash, M. I.
- Affiliations
- University of Oklahoma Health Sciences Center (US)
- Copernicus Therapeutics (United States) (US)
- Corresponding author
- Naash, Muna I.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-18
- Volume
- 22
- Issue
- 8
- Pages
- 1632-1642
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3605833
- OpenAlex
- W2110968074
- Cited by
- 75
- References
- 50
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 2 · 2019: 2 · 2018: 7 · 2017: 7 · 2016: 5 · 2015: 7 · 2014: 8 · 2013: 5
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Molecular Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Southern California
- University of Oklahoma
- National Eye Institute (EY018512, F32EY018512, EY10609, R01EY018656, R01EY022778, EY018656)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- DNA nanoparticles, scaffold/matrix attachment regions, retinal pigment epithelium, RPE65, Leber congenital amaurosis, non-viral gene delivery, persistent gene expression, retinal gene therapy
- MeSH terms
- Bestrophins, Retinoid Isomerohydrolase, Animals, Disease Models, Animal, DNA, Eye Proteins, Gene Expression Regulation, Humans, Organ Specificity, Retinal Degeneration, Genetic Therapy, Chloride Channels, cis-trans-Isomerases, Matrix Attachment Regions, Mice, Nanoparticles, Retinal Pigment Epithelium, Leber Congenital Amaurosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.